Drug data last refreshed 6d ago · AI intelligence enriched 3w ago
MAXAQUIN (lomefloxacin hydrochloride) is an oral fluoroquinolone antibiotic approved in 1992 for bacterial infections. It is a broad-spectrum quinolone that inhibits bacterial DNA gyrase and topoisomerase IV, disrupting DNA replication in susceptible organisms. The drug was primarily indicated for respiratory tract infections, urinary tract infections, and other bacterial infections treatable with fluoroquinolones.
As a legacy fluoroquinolone approaching loss of exclusivity with moderate competitive pressure (30%), the brand team is likely small and focused on maximizing remaining patent-protected revenue or transition planning.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on MAXAQUIN offers minimal career growth potential given its LOE status, zero linked job postings, and mature lifecycle stage. Professionals should view this assignment as a consolidation or cost-management role rather than a springboard for advancement within a growth portfolio.
Worked on MAXAQUIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.